The Global Access Initiative at the University of British Columbia (UBC): Availability of UBC Discoveries and Technologies to the Developing World

Thornton, Sheila J.; Bell, Ian H.; Goulding, Rebecca; Gretes, Michael; Gray, Andrew P.; Hancock, Robert E. W.; Campbell, Barbara

doi:10.1002/jps.21495

Cited by 10 publications

(9 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For one, investigators and directors of research institutes could re-evaluate conditions that define patents on innovations developed through their efforts or at their institutions. Recent policies concerning the patenting of innovations discovered at the University of British Columbia (Canada) is a notable example [107]. Known as the Global Access Initiative , some university polices mandate that patent rights are transferred to corporations under the condition that products commercialized from patented technology will be available to populations of the developing world.…”

Section: Methodsmentioning

confidence: 99%

The paucity of ethical analysis in allergology

Behrmann

2013

All Asth Clin Immun

View full text Add to dashboard Cite

While a growing body of research is uncovering the aetiology and effective treatments for allergy, research that assess the broader ethical implications of this disease is lacking significantly. This article will demonstrate both the paucity of academic research concerning ethical implications in allergy and explain why ethical analysis is integral to formulating effective health strategies for allergic disease. An exhaustive literature search of publications in French and English identified less than 35 academic articles focussed on the topic of ethics and allergy; this is a miniscule number when compared to the amount of articles published on ethical issues related to other chronic illnesses, such as obesity. It is important to demonstrate to allergy specialists the need for, and utility of, further incorporating ethical analyses in allergology; the current success of Ethical, Legal, Social Implications (ELSI) research programmes in human genetics and nanotechnology will serve as notable examples. Indeed, future research and innovation in allergy will undoubtedly encounter ethical dilemmas and the allergology community should play a significant role in helping to address these issues. However, incorporating ethical analyses in allergology does not imply that the allergology community must acquire extensive knowledge in bioethics; instead, interdisciplinary research that incorporates expertise from allergology and bioethics would enable allergy specialists to advance critical knowledge development in this largely overlooked domain of study.

show abstract

Section: Methodsmentioning

confidence: 99%

The paucity of ethical analysis in allergology

Behrmann

2013

All Asth Clin Immun

View full text Add to dashboard Cite

show abstract

“…42 So far, only intravenous formulations of amphotericin B have been licensed. New oral formulations of amphotericin B are in early stages of development as part of the drive to improve access to treatment for visceral leishmaniasis, 43,44 …”

Section: Amphotericin Bmentioning

confidence: 99%

Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries

Loyse

Thangaraj

Easterbrook

et al. 2013

The Lancet Infectious Diseases

160

144

View full text Add to dashboard Cite

“…He cited his own discovery of the novel lipid-based oral formulation of amphotericin B used to treat visceral leishmaniasis and described its licensing by UBC to iCo Therapeutics 15. Technology transfer policies in place at UBC ensured that this technology was made available at or below cost in least-developed countries 16. In parallel, he explained that the drug would be marketed to treat systemic fungal infections in wealthy countries at a higher price.…”

Section: Universities Pdps and Industry Collaborationsmentioning

confidence: 99%

First Universities Allied for Essential Medicines (UAEM) Neglected Diseases and Innovation Symposium

Musselwhite

Maciag

Lankowski

et al. 2012

The American Society of Tropical Medicine and Hygiene

Self Cite

View full text Add to dashboard Cite

Universities Allied for Essential Medicines organized its first Neglected Diseases and Innovation Symposium to address expanding roles of public sector research institutions in innovation in research and development of biomedical technologies for treatment of diseases, particularly neglected tropical diseases. Universities and other public research institutions are increasingly integrated into the pharmaceutical innovation system. Academic entities now routinely undertake robust high-throughput screening and medicinal chemistry research programs to identify lead compounds for small molecule drugs and novel drug targets. Furthermore, product development partnerships are emerging between academic institutions, non-profit entities, and biotechnology and pharmaceutical companies to create diagnostics, therapies, and vaccines for diseases of the poor. With not for profit mission statements, open access publishing standards, open source platforms for data sharing and collaboration, and a shift in focus to more translational research, universities and other public research institutions are well-placed to accelerate development of medical technologies, particularly for neglected tropical diseases.

show abstract

The Global Access Initiative at the University of British Columbia (UBC): Availability of UBC Discoveries and Technologies to the Developing World

Cited by 10 publications

References 9 publications

The paucity of ethical analysis in allergology

The paucity of ethical analysis in allergology

Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries

First Universities Allied for Essential Medicines (UAEM) Neglected Diseases and Innovation Symposium

Contact Info

Product

Resources

About